Partnership forms to enhance potential to identify hit drug candidates

Provider of label-free drug discovery solutions, SAMDI Tech, has joined forces with a provider of products and services that accelerate research and drug development efforts, Charles River Laboratories, to maximise its clients’ opportunities for drug candidate hit finding.

The two-year partnership will see SAMDI Tech’s clients gain access to more than 150,000 sourced molecules from Charles River’s premier collection of lead-like compounds in their drug discovery projects.

“Bringing together a diverse set of high-quality compounds and the benefits of SAMDI technology not only speeds up timelines and maximizes the probability of finding early-stage drug candidates for our clients, it takes them one step closer to clinical trials with a new treatment option,” said Emilio Córdova, PhD, MBA, chief executive officer at SAMDI Tech.

“We are pleased to partner with SAMDI Tech to combine our experience in compiling high-quality screening libraries with their proprietary screening technology,” revealed Jackie Macritchie, senior managing director, discovery, at Charles River. “Leveraging SAMDI Tech’s technology and Charles River’s diversity screening library enhances the potential for identifying hit molecules across a wide range of target classes and disease areas.”